Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Clinics ; 73(supl.1): e558s, 2018. tab, graf
Article in English | LILACS | ID: biblio-974945

ABSTRACT

The name of the family Polyomaviridae, derives from the early observation that cells infected with murine polyomavirus induced multiple (poly) tumors (omas) in immunocompromised mice. Subsequent studies showed that many members of this family exhibit the capacity of mediating cell transformation and tumorigenesis in different experimental models. The transformation process mediated by these viruses is driven by viral pleiotropic regulatory proteins called T (tumor) antigens. Similar to other viral oncoproteins T antigens target cellular regulatory factors to favor cell proliferation, immune evasion and downregulation of apoptosis. The first two human polyomaviruses were isolated over 45 years ago. However, recent advances in the DNA sequencing technologies led to the rapid identification of additional twelve new polyomaviruses in different human samples. Many of these viruses establish chronic infections and have been associated with conditions in immunosuppressed individuals, particularly in organ transplant recipients. This has been associated to viral reactivation due to the immunosuppressant therapy applied to these patients. Four polyomaviruses namely, Merkel cell polyomavirus (MCPyV), Trichodysplasia spinulosa polyomavirus (TSPyV), John Cunningham Polyomavirus (JCPyV) and BK polyomavirus (BKPyV) have been associated with the development of specific malignant tumors. However, present evidence only supports the role of MCPyV as a carcinogen to humans. In the present review we present a summarized discussion on the current knowledge concerning the role of MCPyV, TSPyV, JCPyV and BKPyV in human cancers.


Subject(s)
Humans , Tumor Virus Infections/virology , Polyomavirus/pathogenicity , Polyomavirus Infections/virology , Neoplasms/virology , Virus Activation , Cell Transformation, Viral , Polyomavirus/classification , Polyomavirus/physiology
2.
Infectol. microbiol. clin ; 9(1): 7-18, 1997.
Article in Spanish | LILACS | ID: lil-197008

ABSTRACT

Actualmente se sabe que el 20 por ciento de los cánceres humanos están asociados con virus oncogénicos. El virus papiloma humano con cáncer anogenital, los virus de la hepatitis B y C con carcinoma hepatocelular, el virus Epstein Barr con carcinomas nasofaríngeos y linfomas, el virus de la leucemia-linfoma T con leucemias en el adulto. Un rasgo común en todos los tumores asociados con infección viral es el largo período de latencia entre la infección y la aparición de la neoplasia y la baja proporción de individuos infectados que desarrollan un tumor maligno. Estas observaciones indican que los virus oncogénicos son necesarios pero no suficientes para inducir cáncer, otros factores podrían estar involucrados. Esta actualización resume informaciones recientes acerca de los mecanismos de carcinogénesis viral, en particular, la interacción de oncoproteínas virales y proteínas supresoras tumorales. La inactivación de estas proteínas supresoras podría representar una estrategia común a través de la cual los virus tumorales pueden contribuir a la transformación maligna de la célula


Subject(s)
Humans , Adenoviruses, Human , Carcinoma, Hepatocellular/physiopathology , Causality , Hepatitis B virus/genetics , HTLV-I Infections/complications , HTLV-II Infections/complications , Papillomaviridae/genetics , Polyomavirus/genetics , Oncogene Proteins, Viral/adverse effects , Oncogenic Viruses/pathogenicity , Adenoviruses, Human/pathogenicity , Adenoviruses, Human/physiology , Burkitt Lymphoma/genetics , Carcinogenicity Tests , Carcinoma, Hepatocellular/etiology , DNA Viruses/pathogenicity , Genes, Suppressor/physiology , Hepatitis B virus/pathogenicity , Hepatitis B virus/physiology , Herpesviridae/pathogenicity , Herpesviridae/physiology , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/pathogenicity , HTLV-I Infections/etiology , HTLV-II Infections/etiology , Interferons/therapeutic use , Papillomaviridae/pathogenicity , Papillomaviridae/physiology , Polyomavirus/pathogenicity , Polyomavirus/physiology , Virus Replication/genetics , Retroviridae/pathogenicity , Sarcoma, Kaposi/virology , Viral Vaccines , Oncogenic Viruses/physiology
SELECTION OF CITATIONS
SEARCH DETAIL